Insulin Aspart vs Omentin-1
Head-to-head comparison of Insulin Aspart (Insulin aspart (B28-Asp human insulin analog)) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Insulin Aspart | Omentin-1 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Insulin aspart (B28-Asp human insulin analog) | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 5825.8 Da | ~35 kDa |
| Half-Life | About 1-3 hours | hours |
| Amino Acids | 51 | 313 |
| Typical Dose | 0.05-0.2 U/kg per meal | No approved human dose; research use only |
| Route | Subcutaneous | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 11000 | 82 |
| Research Status | Approved | Pre-clinical |
Insulin Aspart Benefits
- ✓Fast post-meal glucose lowering
- ✓Predictable onset
- ✓Flexible mealtime administration
- ✓Compatible with pump therapy
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Insulin Aspart Dosing
Inject SC immediately before meals|Titrate using glucose monitoring and carbohydrate intake|Can be used in insulin pumps or basal-bolus regimens
Omentin-1 Dosing
not established|not established
Insulin Aspart Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Insulin Aspart
Research consistently shows faster onset and earlier peak action than regular human insulin. It is commonly studied for meal-time glycemic control and pump-based insulin delivery.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.